System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Marc Debled is an expert in Oncology at Institut Bergonié (France). As of September 2026, ScienceLeadR ranks Marc Debled in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Marc Debled has authored 251 publications, the most recent in 2025, and is an investigator in 17 clinical trials, 1 of them ongoing. SLR score: 673 (community average: 125). How the SLR is computed.

LeadR Profile

Marc Debled Institut Bergonié France
673 ScienceLeadR Reputation 673

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1997 - 2025
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 251

Citations

Citations: 9 131 1st author: 23 Last author: 13 Unique author: 0

Main journals

Cancer Res 38
J Clin Oncol 30
Ann Oncol 26
Eur J Cancer 15
Bull Cancer 14

Best Journals

Ann Oncol 11
J Clin Oncol 9
Lancet Oncol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.
PMID 41297161 — lymph nodes, breast neoplasms, neoplasms, immunotherapy, lymph, breast		ESMO Open20251
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD Trial.
PMID 40849898 — aromatase, aromatase inhibitors, breast neoplasms, neoplasms, drug therapy, everolimus, pharmacology, breast, therapeutics, tamoxifen		Clin Pharmacol Ther20250
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
PMID 40752909 — breast neoplasms, neoplasms, drug therapy, aged, drug-related side effects and adverse reactions, chemotherapy, adjuvant, breast, therapeutics, frailty, chemotherapy		Lancet Top journal20251
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial.
PMID 38718683 — therapeutics, breast neoplasms, biomedical research, disease-free survival, tamoxifen, artificial intelligence		EBioMedicine20243
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients.
PMID 38788907 — breast neoplasms, pharmaceutical preparations, chemistry, pharmaceutical, neoplasms, letrozole, hormones, breast, technology, pharmaceutical, pharmacokinetics		Eur J Pharm Sci20243

Clinical Studies 17

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 1

By phase:

Phase 3 9
N/A 4
Phase 2 3
Phase 4 1

By status:

Completed 13
Recruiting 2
Active not recruiting 1
Terminated 1

By type:

Interventional 15
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 2
multicentric5to9 1
multicentricup10 12

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER HER2 Breast Cancer With an ESR1 Mutation
NCT05696626 — fulvestrant, estrogens, safety, breast neoplasms, receptors, estrogen, neoplasms, breast, therapeutics, mutation, men, women		Phase 3Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS